CANbridge Announces Strategic Partnership and Investment from Baheal to Strengthen Commercialization of Rare Disease Products

CANbridge Announces the First Prescription of Gaurunning®, a Class 1 New Drug for Treating Type I and III Gaucher Disease

CANbridge Announces Marketing Approval of Velaglucerase-beta for Injection (Gaurunning), a Class 1 New Drug for Treating Type I and III Gaucher Disease, in China

CANbridge Announces that Velaglucerase-beta for Injection Successfully Passed the Pre-approval inspection and Pre - marketing GMP Compliance Inpection for the Pilot Biological Product of Divided manufacturing

CANbridge Announces Expansion of Livmarli® Label to Include ALGS Patients as Young as 2 Months in Taiwan

CANbridge Announces Marketing Approval of Livmarli® in Taiwan for the Treatment of Cholestatic Pruritus in PFIC Patients

CANbridge and Scriptr Global Announce Publication in the Journal Science Reporting the Discovery of the StitchR™ RNA Assembly Technology and its Application for the Treatment of Muscular Dystrophies

CANbridge Pharmaceuticals CAN103 New Drug Application (NDA), for Gaucher disease, Accepted by China’s National Medical Products Administration

CANbridge Pharmaceuticals Successfully Obtains Drug Manufacturing License Type B Certificate

CANbridge Pharmaceuticals’ CAN103 for Gaucher Disease Granted Priority Review Status by CDE of the NMPA